COVID-19 NIH Updates

The Health Sciences Sponsored Project Pre-Award Office will remain open and operational and will continue to provide service to our department partners, faculty, academics, physicians, and scholars. Because of the evolving situation with COVID-19 and because the health and welfare of our staff and their families is of highest priority, we are providing our teams with the flexibility they need in terms of telecommuting while maintaining our commitment to our clients and the organization. We expect some adjustments as we adapt to operating in these uncertain and rapidly changing times, and we appreciate and thank you for your understanding and patience. Please note, these workplace adjustments will not impact your ability to reach out to your current HS SPPO contacts who will continue to be available to help.

If you have any questions, please e-mail eswilson@health.ucsd.edu

+ Expand All

UC & UC San Diego Updates Related to COVID-19

UC Office of the President: How UC is Responding to the Coronavirus (COVID-19)

Memo: Charging grants and contracts costs to Federal sponsored awards during COVID-19 (3/24/2020)

UC San Diego: COVID-19 Information
UC San Diego - IACUC: Current Operational Status in Response to Coronavirus Pandemic
UC San Diego - Health: Novel Coronavirus (COVID-19) Information
UC San Diego - HRPP: UCSD IRB Updates Regarding COVID-19
UC San Diego - OCGA: Guidance from Sponsors and Research Partners Regarding the Impact of COVID-19 on Research
UC San Diego - Office of Research Affairs (ORA): COVID-19: Continuity of Research

At-a-Glace summary of Federal sponsor guidance regarding COVID-19 flexibilities affecting contracts and grants: At a glance summary
Links to detailed sponsor guidance regarding impacts of COVID-19 on contract and grant administration: Guidance from Sponsors and Research Partners
FAQ’s related to COVID-19 impact on contracts and grants: FAQ’s
COVID-19 Funding Opportunities and Resources: Funding Opportunities and Multi-campus Research Programs and Initiatives RFP
Letter stating that regardless of COVID-19-related lab closures, research on COVID-19 or SARS-CoV-2 will still be allowed to proceed at UC San Diego: Institutional Support Letter for COVID-19 Research Applications

NIH Updates, FOAs, and NOSIs Related to COVID-19

NIH-Wide Strategic Plan for COVID-19 Research (7/13/2020)

COVID-19 Information for NIH Applicants and Recipients

COVID-19 FAQs for COVID-19 Flexibilities for Applicants and Recipients

Update on COVID-19 Flexibilities for the Research Community on YouTube (posted 3/26/2020)

Dr. Mike Lauer, NIH Deputy Director for Extramural Research, provides updates for the research community on flexibilities NIH is providing the community due to the COVID-19 public health emergency.

NIH Message to Applicants and Recipients of NIH Funds on Flexibilities Needed for COVID-19 on YouTube (posted 3/17/2020)

Dr. Mike Lauer, NIH Deputy Director for Extramural Research, provides an update for applicants and recipients of federal funding on flexibilities NIH has put in place to support them and their research through the disruptions caused by COVID-19.

Notices

NOT-GM-20-026	Guidance for Cost-Related Flexibilities Available to Support of Competitive Research (SCORE) Award Recipients Affected by COVID-19
NOT-OD-20-088	Flexibilities for Assured Institutions for Activities of Institutional Animal Care and Use Committees (IACUCs) Due to COVID-19
NOT-HS-20-010	Flexibilities Available to AHRQ Recipients and Applicants Directly Impacted by the Novel Coronavirus (COVID-19) Due to Loss of Operations
NOT-OD-20-091	UPDATE: NIH Late Application Policy Due to Public Health Emergency for United States for 2019 Novel Coronavirus (COVID-19
NOT-HS-20-007	Notice of Intent: Revision Supplements to Existing AHRQ Grants and Cooperative Agreements to Address Health System Responsiveness to COVID-19
NOT-HS-20-008	Notice of Intent: New Funding Opportunity Announcement to Support Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19
NOT-OD-20-087	Guidance for NIH-funded Clinical Trials and Human Subjects Studies Affected by COVID-19
NOT-OD-20-086	Flexibilities Available to Applicants & Recipients of Federal Financial Assistance Affected by COVID-19
NOT-OD-20-083	General FAQs - Proposal Submission and Award Management Related to COVID-19
NOT-OD-20-082	NIH LATE APPLICATION POLICY Due to Public Health Emergency for US for COVID-19
NOT-CA-20-054	Notice of Information: Contributing to the Global COVID-19 Crisis Response by Allowing Some NCI-supported Projects to be Redirected to COVID-19-related Research During the Crisis
NOT-OD-20-103	Notice of Additional Due Date and Additional “Areas of Focus Especially of Interest” of PAR-19-373 and PAR-19-384, "Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01)"
NOT-OD-20-105	NIH Late Application Policy for Institutional Training Grants to PA-20-142 and PA-20-162 Due to Public Health Emergency for United States Coronavirus Disease 2019 (COVID-19)
NOT-AG-20-033	NIA Late Application Policy for NIA-Specific FOAs with Application Due Dates in May, June, and July 2020
NOT-HD-20-016	NICHD Late Application Policy for Institutional Training Grants to RFA-HD-21-014 Due to Public Health Emergency for United States Coronavirus Disease 2019 (COVID-19)
NOT-HG-20-041	RESCINDED - NHGRI Late Application Policy for NHGRI-Specific FOAs with Application Due Dates in May, June, and July
NOT-EB-20-012	Notice of Change in Application Due Date for PAR-19-215 Due to Public Health Emergency for United States Coronavirus Disease 2019 (COVID-19)
NOT-CA-20-069	Notice of Change: Late Application Policy for June 17, 2020, Application Due Date of PAR-19-242, Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional) Due to Public Health Emergency for US Coronavirus Disease 2019
NOT-OD-20-110	Reissue of Parent Announcements (PA-18-589, PA-18-590, PA-18-591, and PA-18-592) and the Urgent (PA-18-935) and Emergency (PA-20-135) Competitive Revision FOAs is Underway - Continue to use the Current Announcements and Forms Packages Until Reissuance
NOT-CA-20-072	NCI Late Application Policy for NCI-Specific RFAs with Application Due Date of June 24, 2020
NOT-AI-20-053	NIAID Late Application Policy for NIAID-Specific RFAs with Due Dates in June 2020
NOT-OD-20-112	Notice of Intent to Publish Funding Opportunity Announcements for the RADx-UP Initiatives
NOT-MD-20-023	Notice of Intent to Publish a Funding Opportunity Announcement for Community Interventions to Address the Consequences of the COVID-19 Pandemic for Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional)
NOT-MH-20-058	Notice of Intent to Publish a Funding Opportunity Announcement for Digital healthcare interventions to address the secondary health effects related to social, behavioral, and economic impact of COVID-19 (R01 - Clinical Trial Optional)
NOT-MH-20-061	Notice Announcing the Availability of Common Data Elements for Research Related to the Public Health Emergency caused by Coronavirus Disease 2019 (COVID-19)
NOT-OD-20-123	Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy During the COVID-19 Pandemic
NOT-OD-20-118	Guide Notice of Information Highlighting Harmonization and Data Sharing Expectations for Supplement and Revision Projects Addressing Social, Behavioral, Economic and Health Impacts of the COVID-19 Public Health Emergency
NOT-NS-20-076	Notice to Extend Eligibility for Submission of Diversity K22 Applications due to COVID–related Disruptions
NOT-OD-20-122	Guidance for Applicants Preparing Applications for the Fall 2020 Due Dates During the COVID-19 Pandemic
NOT-OD-20-163	Extending the Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy During the COVID-19 Pandemic
NOT-OD-20-162	Request for Information (RFI): Inviting Comments and Suggestions on University-Based Approaches for COVID-19 Surveillance Testing to Review the Current Landscape)

FOAs

PA-20-163	Competing Revisions to Existing NIH Grants and Cooperative Agreements (Clinical Trial Optional)	This needs to be used in conjunction with COVID-19 specific NOSIs.
PA-20-135	Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)	This needs to be used in conjunction with COVID-19 specific NOSIs.
PA-18-935	Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)	This needs to be used in conjunction with COVID-19 specific NOSIs.
PA-18-591	Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)	This needs to be used in conjunction with COVID-19 specific NOSIs.
RFA-AI-20-028	Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed)	NIAID IC specific FOA. This FOA will support development of a candidate therapeutic against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19 as well as this FOA will support development of a candidate vaccine against SARS-CoV-2, the virus that causes COVID-19. Due Date: applications are due by June 29, 2020.
PA-20-070	Competitive Revision Supplements to Existing AHRQ Health Service Research (HSR) Grants and Cooperative Agreements to Evaluate Health System and Healthcare Professional Responsiveness to COVID-19 (Supplement - Clinical Trial Optional)	Competitive revision requests may be submitted electronically for active AHRQ awards (except R13s, T32s, F32s). This FOA does not include grants that were previously funded under Patient Centered Outcome Research Trust Fund (PCOR TF) dollars. Due Date: applications are due by May 29, 2020.
PA-20-072	Competitive Revision Supplements to Existing AHRQ Patient Centered Outcomes Research (PCOR) Grants and Cooperative Agreements to Evaluate Health System and Healthcare Professional Responsiveness to COVID-19 (Supplement - Clinical Trial Optional)	Competitive revision requests may be submitted electronically for active AHRQ awards that were funded under the certain PCOR FOAs. Applicants should apply to this PA, using the activity code of the grant type mechanism of the parent grant for which they are requesting a supplement. Due Date: applications are due by May 29, 2020.
PAR-20-177	Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed)	The purpose of this FOA is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). Due Date: applications will be accepted on a rolling basis, beginning on 04/30/2020 till 8/14/2020. NOT-AI-20-063: Notice of expiration date.
PAR-20-178	Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed)	The purpose of this FOA is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). Due Date: applications will be accepted on a rolling basis, beginning on 04/30/2020 till 8/14/2020. NOT-AI-20-062: Notice of expiration date.
RFA-HS-20-003	Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19 (R01)	The purpose of this FOA invites R01 grant applications for funding to support novel, high-impact studies evaluating the responsiveness of healthcare delivery systems, healthcare professionals, and the overall U.S. healthcare system to the COVID-19 pandemic. Due Date: June 15, 2020.
RFA-CA-20-039	Emergency Awards: Research Projects in SARS-CoV-2 Serological Sciences (U01 Clinical Trial Optional)	The purpose of the FOA is to establish Serological Sciences Research Projects with the goals of: identifying and advancing research opportunities to characterize the immune responses elicited by SARS-CoV-2 viral infection; understanding the mechanisms driving the serological, humoral and cellular immune responses; determining host, genetic, and environmental modifiers of the immune response; determining the serological correlates of disease pathogenesis and protection against future infection; and defining access, communication, and implementation barriers related to SARS-CoV-2 serological testing. Due Date: July 22, 2020. NOT-CA-20-076: Notice of Clarification to Key Dates.
RFA-CA-20-038	Emergency Awards: SARS-CoV-2 Serological Sciences Centers of Excellence (U54 Clinical Trial Optional)	The purpose of the FOA is to establish Serological Sciences Centers of Excellence with the goal of identifying and advancing research opportunities to characterize the immune responses elicited by SARS-CoV-2 viral infection; understanding the mechanisms driving the serological, humoral and cellular immune responses; determining host, genetic, and environmental modifiers of the immune response; determining the serological correlates of disease pathogenesis and protection against future infection; defining access, communication, and implementation barriers related to SARS-CoV-2 serological testing. Due Date: July 22, 2020.
RFA-OD-20-013	Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional)	This emergency cooperative agreement funding opportunity announcement (FOA) from the National Institutes of Health (NIH) provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Underserved Populations (RADx-UP) initiative, a consortium of community-engaged research projects to understand factors that have led to disproportionate burden of the pandemic on the underserved and/or vulnerable populations so that interventions can be implemented to decrease these disparities. This FOA seeks to fund a single Coordination and Data Collection Center (CDCC) as an integral part of the consortium. Due Date: August 7, 2020. NOT-OD-20-140: Notice of Corrections to RFA-OD-20-013 "Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional)" Budget and Review
PAR-20-234	NIA Multi-site COVID-19 Related Clinical Trial Implementation Grant on Aging-Related Topics in at-risk Older Adult Populations (R01 Clinical Trial Required)	This FOA invites applications for implementation of investigator-initiated multi-site clinical trials (all phases or stages) of interventions focused on specific aging-related issues to reducing transmission, risk, morbidity, mortality, severity, or complications of Coronavirus Disease 2019 (COVID-19). Due Date: July 1, 2020; August 3, 2020; September 1, 2020; October 1, 2020; November 2, 2020; December 1, 2020; January 4, 2021; and February 1, 2021.
PAR-20-237	Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional)	This FOA encourages applications to implement and evaluate community interventions testing 1) the impacts of mitigation strategies to prevent COVID-19 transmission in NIH-designated health disparity populations and other vulnerable groups; and 2) already implemented, new, or adapted interventions to address the adverse psychosocial, behavioral, and socioeconomic consequences of the pandemic on the health of these groups. Due Date: August 28, 2020; December 1, 2020
PAR-20-243	Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01 - Clinical Trial Optional)	This FOA aims to support research to strengthen the healthcare response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and future public health emergencies, including pandemics. While research related to the direct clinical effects of COVID-19 are supported by other funding opportunities, the purpose of this funding opportunity is to focus on the role and impact of digital health interventions [e.g., mobile health (mhealth), telemedicine and telehealth, health information technology (IT), and wearable devices] to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions for secondary effects (e.g., behavioral health or self-management of chronic conditions) that are utilized during and following the pandemic, particularly in populations who experience health disparities and vulnerable populations. Due Date: August 20, 2020, December 2, 2020, March 2, 2021.
RFA-DK-20-021	Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and Diseases and Organ Systems of Interest to NIDDK (R01 Clinical Trial Optional)	The purpose of this FOA is to support basic and clinical mechanistic research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) susceptibility, routes of infection, course of disease, morbidity and mortality in people with pre-existing diseases, or adverse acute or chronic outcomes in organs, tissues, and biological systems of specific interest to NIDDK. These include diabetes and other metabolic diseases, obesity, and endocrine, digestive, liver, pancreas, kidney, urological, and hematologic tissues and diseases. Due Date: December 16, 2020.
PAR-20-256	Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed)	The purpose of this public health emergency funding opportunity is to provide Personal Protective Equipment (PPE) to directly support the needs of the NIAID’s vaccine and treatment clinical trials and clinical studies for COVID-19. This program will ensure that adequate protective equipment is available to directly assist in safely carrying out the clinical activities and direct interactions with the patients participating in the trial. Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAID’s emergency appropriation provided by “The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020” and “The Coronavirus Aid, Relief and Economic Security (CARES) Act”. Due Date: applications for this limited competition FOA will be accepted on a rolling basis, beginning July 13, 2020 till July 7, 2021.
RFA-TR-20-003	Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required)	The purpose of this urgent funding opportunity announcement is to invite applications to repurpose existing therapeutic agents to treat Coronavirus Disease 2019 (COVID-19) sequelae and associated complications that result from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections. The therapeutic agent must have already completed at least a Phase I clinical trial for a different indication, and not require additional regulatory studies for the new indication prior to starting a clinical trial. Due Date: Applications will be accepted on a rolling basis, beginning on August 6, 2020 till January 23, 2021.
RFA-OD-20-014	Emergency Awards: Automatic Detection and Tracing of SARS-CoV-2 (U01 Clinical Trial Not Allowed)	This RFA will support the early stage development of an innovative platform that integrates biosensing with touchscreen or other digital devices to achieve detection and tracing of SARS-CoV-2 in real-time. Projects are expected to demonstrate proof-of-concept of SARS-CoV-2 detection with high sensitivity and specificity, sensor functionality, and automatic detection by touchscreen or other digital devices. To achieve the goal of this FOA, the proposed project needs to be milestone driven and carried out by a multidisciplinary team with complementary expertise. Due Date: 09/15/2020.
RFA-OD-20-015	Emergency Awards: RADx-rad Wastewater Detection of SARS-COV-2 (COVID-19) (U01 - Clinical Trials Not Allowed)	The purpose of this FOA is to solicit cooperative agreements both for field studies and for small business research and development projects in the field of WBT, to address topics such as: investigation and demonstration of specific approaches aiming to increase sensitivity and to inform and optimize sample collection; implementation and development of optimized approaches to extrapolate estimation of population-level data within the community; development of optimized intervention strategies, and incorporation of computational, statistical, and mathematical models. Due Date: 09/15/2020.
RFA-OD-20-016	Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional)	This FOA invites applications to pursue development and validation studies of COVID-19 surveillance methods, not based or focused on direct viral testing of individuals, in settings and institutions, including residential, with a high density of individuals who are together for prolonged periods of time. There are numerous promising technologies which could allow for multimodal surveillance inputs. However, these technologies are often not interoperable, not optimized for integration to increase robustness and not tested for general applicability to public health or for the specific need of high-risk population surveillance. Applications are invited that translate a combination of digital surveillance modalities into platforms that can assist the professional staff of high-risk facilities in making clinically meaningful care recommendations for patients at risk of COVID-19 or other respiratory viruses. Projects proposed may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Due Date: 09/30/2020.
RFA-OD-20-017	Emergency Awards RADx-RAD: Screening for COVID-19 by Electronic-Nose Technology (SCENT) (U18 Clinical Trial Not Allowed)	This FOA is seeking applications for a portable sensing device to detect volatile organic compounds (VOCs, i.e., scents or odors) emanating from skin or exhaled breath, saliva and different oral tissues from the oral cavity. Additionally, this FOA seeks to advance novel biosensing technologies that are innovative, safe, and effective using integrated artificial intelligent, pattern recognition and machine learning systems that would make it possible for the detection, diagnosis, prediction, and monitoring of COVID-19 in clinical, community and everyday settings. Due Date: 09/18/2020.
RFA-OD-20-018	Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS-CoV-2 (U18 Clinical Trial Not Allowed)	This FOA seeks to use developed technologies for single vesicle or exosome isolation and analysis and reposition these technologies for the detection of SARS-CoV-2. Due Date: 09/18/2020.
RFA-OD-20-019	Emergency Awards: RADx-rad Data Coordination Center (DCC) (U24 Clinical Trial Not Allowed)	This FOA seeks to fund a single cooperative agreement for a Data Coordination Center (DCC) to serve as a communication center and data hub for RADx-rad awardees. Due Date: 09/30/2020.
RFA-OD-20-022	Emergency Awards: Chemosensory Testing as a COVID-19 Screening Tool (U01 Clinical Trial Optional)	The goal of the RADx-rad initiative is to encourage the development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus or other markers of the COVID-19 disease that can be used in future outbreaks of COVID-19 and that could be applicable to other, as yet unknown, viruses. Specifically, the goal of this FOA is to solicit applications to enhance the utility of chemosensory testing as a COVID-19 screening tool by using objective tests to examine the onset and prognostic value of chemosensory loss and to encourage the development and/or deployment of home-based and on-site chemosensory tests. Due Date: 09/15/2020.
RFA-OD-20-023	Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kIds) (R61/R33 Clinical Trial Optional)	This FOA seeks to support innovative research to develop novel, new or unique and non-traditional approaches (e.g. diagnostic and prognostic biomarkers and/or biosignatures) to identify and characterize the spectrum of SARS CoV-2 associated illness, including the multisystem inflammatory syndrome in children (MIS-C) and, through a prognostic algorithm, predict the longitudinal risk of disease severity after a child is exposed to and may be infected with SARS-CoV-2 to properly tailor his or her management and optimize health outcomes. Due Date: 09/30/2020.

NOSIs

You can learn more about NOSI’s in this quick 5 minute video.

NOT-AI-20-030	Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV)	NIGMS NIAID	*This notice was rescinded on 4/9/2020. It was replaced by NOT-AI-20-034 for NIAID competitive revisions and NOT-GM-20-025 for NIGMS competitive revisions. Update: Per NOT-AI-20-040, this NOSI expired 4/9/2020 and was replaced with NOT-AI-20-034 for NIAID competitive revisions and NOT-GM-20-025 for NIGMS competitive revisions.
NOT-HL-20-757	Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)	NHLBI	Applications in response to this NOSI must be submitted using the following targeted funding opportunity: PA-18-935 is intended to provide funds for NIH grantees applying to expand the scope of their active grant. PA-18-591 is intended to provide funds for NIH grantees where the work proposed in the supplement is fully within the scope of the ongoing grant. Update: NOT-HL-20-759: NHLBI Announces Availability of FAQs for NOT-HL-20-757. Update: NOT-HL-20-789: Notice of Expiration of NOT-HL-20-757 "Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)" Due Date: applications will be accepted on a rolling basis from March 17, 2020 through October 5, 2020.
NOT-DA-20-047	Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus	NIDA	Applications in response to this NOSI must be submitted using the following targeted funding opportunity: PA-18-935 is intended to provide funds for NIH grantees applying to expand the scope of their active grant. PA-18-591 is intended to provide funds for NIH grantees where the work proposed in the supplement is fully within the scope of the ongoing grant. Due Date: applications will be accepted on a rolling basis through March 31, 2021.
NOT-TR-20-011	Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need	NCATS	CTSA (CTRI) award specific. PA-18-591 for UL1, U01, and R21 awards; PAR-19-099 for U01 specific awards; PAR-19-100 for R21 specific awards; PAR-19-337 for UL1 specific awards. Update: NOT-TR-20-018 expands the eligibility and activity codes to include U24 parent awards. Due Date: varies per award mechanism and FOA. See NOSI.
NOT-GM-20-025	Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2	NIGMS	NIGM issued this NOSI to highlight the urgent need for research on SARS-CoV-2 and Coronavirus Disease 2019 (COVID-19). Applications in response to this NOSI must be submitted to PA-18-935 which is intended to provide funds for NIH grantees applying to expand the scope of their active grant. Due Date: applications will be accepted on a rolling basis from March 25, 2020 to February 5, 2021.
NOT-AI-20-034	Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)	NIAID	This Notice was rescinded and was replaced by NOT-AI-20-059 which highlights very specific needs for competitive revision applications to NIAID grants to facilitate the Federal SARS-CoV-2/COVID-19 research response. NIAID issued this NOSI to highlight the need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). Applications in response to this NOSI must be submitted using the following targeted funding opportunity: PA-20-135 is intended to provide funds for NIH grantees applying to expand the scope of their active grant. The funding instrument, or activity code, will be the same as the parent award. All activity codes of currently funded NIAID grants are eligible. Please note: NOT-AI-20-034 is specific for PA-20-135. NIH grantees seeking additional funds for research responsive to the SARS-CoV-2/COVID-19 outbreak that falls within the scope of an ongoing grant should instead apply for an administrative supplement under NIH PA-18-591. Due Date: applications will be accepted on a rolling basis from 03/25/2020 through 03/25/2021.
NOT-ES-20-014	Notice of Special Interest: NIEHS Worker Training Program Coronavirus and Infectious Disease Response Training (Admin Supp Clinical Trial Not Allowed)	NIEHS	This was rescinded 4/10/2020. This was replaced by NOT-ES-20-017.
NOT-AI-20-031	Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)	NIAID	Submit applications for this initiative using one of the following FOAs or any reissues of these announcement through the expiration date of this notice: PA-19-052: Parent R03 Clinical Trial Not Allowed PA-19-053: Parent R21 Clinical Trial Not Allowed PA-18-591: Parent Admin Supp - Clinical Trial Optional) PA-19-056: Parent R01 Clinical Trial Not Allowed PA-19-272: Parent SBIR [R43/R44] Clinical Trial Not Allowed PA-19-270: Parent STTR [R41/R42] Clinical Trial Not Allowed Due Date: applications for PA-18-591 will be accepted on a rolling basis from April 5, 2020 through while the other FOAs applies to due date on or after April 5, 2020 and subsequent receipt dates through April 5, 2021. This was rescinded as of May 19, 2020. NIAID has issued NOT-AI-20-051 in its place.
NOT-TR-20-012	Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)	NCATS	Urgent need for research on the 2019 novel coronavirus (SARS-CoV-2) and the disease it causes. NCATS is soliciting applications to PAR-17-465 (UG3/UH3), PAR-18-462 (U34), and PAR-18-332 (U01). Due Date: UG3/UH4 due June 26, 2020; U34 due June 16, 2020 & October 16, 2020; and U01 due June 5, 2020 & October 5, 2020.
NOT-AG-20-022	Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)	NIA	Administrative supplement work that is proposed through PA-18-591 must be within the general scope of the research or training that is already supported. Applications that involve a change in scope (e.g., the addition of human subjects to a grant that has not been previously so coded and approved, the addition of vertebrate animals to a grant that has not been previously so coded and approved) must apply through PA-18-935. An FAQ page was created to assist those interested in applying to this NOSI. It can be found here. Due Date: applications will be accepted on a rolling basis from April 6, 2020 through May 1, 2021.
NOT-DC-20-004	Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19)	NIDCD	Only R01 and U01 activity codes of currently funded NIDCD grants are eligible to apply to this NOSI. Administrative supplement work that is proposed through PA-18-591 must be within the general scope of the research or training that is already supported. Applications that involve a change in scope (e.g., the addition of human subjects to a grant that has not been previously so coded and approved, the addition of vertebrate animals to a grant that has not been previously so coded and approved) must apply through PA-18-935. Due Date: applications will be accepted on a rolling basis from April 7, 2020 to June 1, 2020.
NOT-DK-20-018	Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK	NIDDK	NIDDK will only consider applications that propose projects that may lead to rapid translation and impact in the COVID-19 emergency to be responsive to this NOSI. Submit applications for this initiative using the following funding opportunity announcement (FOA): PA-18-935. Due Date: June 1, 2020. Update: NOT-DK-20-026 adds the U24 activity code to the activity codes eligible for submissions and adjust the language for parent awards to be eligible.
NOT-ES-20-015	Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)	NIEHS	This was rescinded on 4/10/2020. It was replaced by NOT-ES-20-020.
NOT-TR-20-016	Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus	NCATS	Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent: PA-18-591. Due Date: applications will be accepted on a rolling basis from May 15, 2020 through January 25, 2022.
NOT-MH-20-047	Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus	NIMH NIA NIAAA NIMHD ODP	Administrative supplement work that is proposed through PA-18-591 must be within the general scope of the research or training that is already supported. Applications that involve a change in scope (e.g., the addition of human subjects to a grant that has not been previously so coded and approved, the addition of vertebrate animals to a grant that has not been previously so coded and approved) must apply through PA-18-935. Due Date: applications will be accepted on a rolling basis through April 15, 2021.
NOT-TR-20-017	Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus	NCATS	PA-20-135 or its reissued equivalent must be used for submissions for this initiative. Due Date: applications will be accepted on a rolling basis from May 15, 2020 to January 25, 2022.
NOT-MD-20-019	Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities	NIMHD NIA NIMH	Administrative supplement work that is proposed through PA-18-591 must be within the general scope of the research or training that is already supported. Applications that involve a change in scope (e.g., the addition of human subjects to a grant that has not been previously so coded and approved, the addition of vertebrate animals to a grant that has not been previously so coded and approved) must apply through PA-18-935. Due Date: applications will be accepted on a rolling basis from May 01, 2020 through May 01, 2021. NOT-MD-20-024: Notice of Information for Date of Submission to NOT-MD-20-019 and NIMHD Consideration for FY Award informs that all applications received by 5:00 PM on July 15, 2020 will be considered for funding in FY2020. Applications to NIMHD which are received after 5:00 PM (local time of the applicant institution) on July 15, 2020 may be held for consideration in Fiscal Year 2021 and not be eligible for funding before October 2020
NOT-DK-20-020	Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) Related to HIV Comorbidities, Coinfections, and Complications within NIDDK's Mission	NIDDK	Submit applications for this initiative using the following funding opportunity announcement (FOA) or its subsequent reissued equivalent: PA-18-935. Projects with one or more components that are not aligned with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR) in NOT-OD-20-018 will not be supported by this FOA. Due Date: June 1, 2020.
NOT-CA-20-042	Notice of Special Interest (NOSI): National Cancer Institute Announcement Regarding Availability of Urgent Competitive Revision and Administrative Supplements on Coronavirus Disease 2019 (COVID-19)	NCI	Administrative supplement work that is proposed through PA-18-591 must be within the general scope of the research or training that is already supported. Applications that involve a change in scope (e.g., the addition of human subjects to a grant that has not been previously so coded and approved, the addition of vertebrate animals to a grant that has not been previously so coded and approved) must apply through PA-18-935 which is limited to the following mechanisms: P01; P30; P50; R00; R01; R33; R35; R37; U01; U19; U24; and U54. Due Date: applications will be accepted on a rolling basis from April 14, 2020, through June 25, 2020.
NOT-AT-20-011	Notice of Special Interest (NOSI): Availability of Administrative Supplements and Urgent Competitive Revisions for Research on Stress Management in Relation to Coronavirus Disease 2019 (COVID-19)	NCCIH NIA NIAAA	Administrative supplement work that is proposed through PA-18-591 must be within the general scope of the research or training that is already supported. Applications that involve a change in scope (e.g., the addition of human subjects to a grant that has not been previously so coded and approved, the addition of vertebrate animals to a grant that has not been previously so coded and approved) must apply through PA-18-935. Due Date: applications will be accepted on a rolling basis through October 6, 2020.
NOT-EB-20-008	Notice of Special Interest (NOSI): Availability of Emergency Competitive Revision and Administrative Supplements on Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)	NIBIB	Applications in response to this NOSI must be submitted using one of the following target opportunities or subsequently reissued equivalents: PA-20-135, which is intended to provide funds for NIH grantees applying to expand the scope of their active grant and are limited to the following mechanisms: DP1, DP2, P41, R00, R01, R03, R15, R21, R24, R37, R41, R43, R44, R56, U01, U18, U24, U2C, U54, UG3, UH2, UH3. PA-18-591, which is intended to provide additional funds for NIH grantees for work that falls within the scope of their active grant. Due Date: applications will be accepted immediately and on a rolling basis through November 10, 2020.
NOT-ES-20-017	NIEHS Worker Training Program Coronavirus and Infectious Disease Response Training (Admin Supp Clinical Trial Not Allowed)	NIEHS	Must have an applicable award as noted in NOSI. Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent: PA-20-135. This replaced NOT-ES-20-014. Due Date: April 24, 2020.
NOT-GM-20-027	Notice of Special Interest (NOSI): Urgent Competitive Revisions to Accelerate Research on the Development of Predictive Models of the Spread of SARS-CoV-2 and Outcomes of Potential Public Health Interventions on COVID-19	NIGMS	Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent: PA-20-135. Due Date: May 5, 2020.
NOT-EB-20-007	Notice of Special Interest (NOSI): Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)	NIBIB	Applications in response to this NOSI must be submitted using one of the following target opportunities or subsequently reissued equivalent: PA-19-056: Parent R01 Clinical Trial Not Allowed PA-18-418: NIBIB Research Project Grant (R01 Clinical Trial Required) PAR-18-530: Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional) PAR-20-155: Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional) PAR-20-084: NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional) PAR-18-433: NIBIB Exploratory/Developmental Research Grant Program (R21 Clinical Trial Optional) PA-19-052: Parent R03 Clinical Trial Not Allowed Due Date: R01 opportunities is June 5, 2020 & R21 opportunities is June 16, 2020.
NOT-ES-20-020	Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)	NIEHS	This replaced NOT-ES-20-015. Administrative supplement work that is proposed through PA-18-591 must be within the general scope of the research or training that is already supported. Applications that involve a change in scope (e.g., the addition of human subjects to a grant that has not been previously so coded and approved, the addition of vertebrate animals to a grant that has not been previously so coded and approved) must apply through PA-18-935. If you are applying for a new R21 grant that does not build off of an existing NIEHS grant, apply to RFA-ES-19-011. Due Date: application Due Dates for all programs: May 1, 2020; June 1, 2020; July 1, 2020; August 3, 2020; September 1, 2020; October 1, 2020; November 2, 2020; December 1, 2020; January 4, 2021; February 1, 2021; March 1, 2021; April 1, 2021; May 3, 2021.
NOT-OD-20-097	Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences	OBSSR NHLBI NIA NIAAA NIDDK NIEHS NCCIH NCI	Administrative supplement work that is proposed through PA-18-591 must be within the general scope of the research or training that is already supported. Applications that involve a change in scope (e.g., the addition of human subjects to a grant that has not been previously so coded and approved, the addition of vertebrate animals to a grant that has not been previously so coded and approved) must apply through PA-18-935. Due Date: applications will be accepted on a rolling basis through March 31, 2021.
NOT-LM-20-010	Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19)	NLM	Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent: PA-18-591. Due Date: June 1, 2020.
NOT-AA-20-011	Notice of Special Interest: Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIAAA	NIAAA	Administrative supplement work that is proposed through PA-18-591 must be within the general scope of the research or training that is already supported. Applications that involve a change in scope (e.g., the addition of human subjects to a grant that has not been previously so coded and approved, the addition of vertebrate animals to a grant that has not been previously so coded and approved) must apply through PA-18-935. Due Date: applications will be accepted on a rolling basis through April 15, 2021.
NOT-TR-20-028	Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions and Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs	NCATS	CTSA (CTRI) award specific. Due Date: applications will be accepted immediately and on a rolling basis through November 10, 2020.
NOT-RM-20-015	Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)	Common Fund	Common Funds award specific. Eligible activity codes for applications to PA-20-135 are limited to the following mechanisms: D43, DP2, DP5, DP7, R01, R24, R25, R35, U01, U18, U19, U24, U2C, U2R, U42, U54, UG3, UH2, UH3, and UM1. Other transaction awards are not eligible. Applications in response to this NOSI must be submitted using: PA-20-135. Due Date: applications will be accepted on a rolling basis from April 15, 2020 through June 19, 2020.
NOT-LM-20-011	Notice of Special Interest (NOSI): Data Driven Research on Coronavirus Disease 2019 (COVID-19) (R21)	NLM	Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice: PA-19-053 (Parent R21 Clinical Trial Not Allowed). Due Date: June 16, 2020.
NOT-HL-20-782	Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions on Coronavirus Disease 2019 (COVID-19) for Currently Active NHLBI Phase I-III Clinical Trials	NHLBI	Applications for this initiative must be submitted to PA-20-135 or its subsequent reissued equivalent. Due Date: applications will be accepted on a rolling basis from May 1, 2020 through July 31, 2020. NOT-HL-20-800: early expiration of NOSI. End date changes from October 5, 2020 to July 31, 2020.
NOT-NS-20-051	Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System	NINDS NIAAA	Administrative supplement work that is proposed through PA-18-591 must be within the general scope of the research or training that is already supported. Applications that involve a change in scope (e.g., the addition of human subjects to a grant that has not been previously so coded and approved, the addition of vertebrate animals to a grant that has not been previously so coded and approved) must apply through PA-18-935. Due Date: June 1, 2020 & November 2, 2020. NOT-NS-20-074: Notice of Change to Eligible Activity Codes
NOT-DE-20-022	Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements for Coronavirus Disease 2019 (COVID-19) Research within the Mission of NIDCR	NIDCR	Administrative supplement work that is proposed through PA-18-591 must be within the general scope of the research or training that is already supported. Applications that involve a change in scope (e.g., the addition of human subjects to a grant that has not been previously so coded and approved, the addition of vertebrate animals to a grant that has not been previously so coded and approved) must apply through PA-18-935. Due Date: June 1, 2020 & November 2, 2020. NOT-DE-20-025: notice of FAQs for this NOSI
NOT-AI-20-051	Notice of Special Interest (NOSI): Select Research Areas for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)	NIAID	Submit applications for this initiative using one of the following FOAs or any reissues of these announcement through the expiration date of this notice: PA-20-200: Parent R03 Clinical Trial Not Allowed PA-19-272: Parent SBIR [R43/R44] Clinical Trial Not Allowed PA-19-270: Parent STTR [R41/R42] Clinical Trial Not Allowed Due Date: applications will be accepted for due dates on or after June 16, 2020 and subsequent receipt dates through September 8, 2020. NOT-AI-20-066: Notice of early expiration from 2021 to 2020.
NOT-AT-20-012	Notice of Special Interest (NOSI): Availability of Administrative Supplements & Urgent Competitive Revisions to NCCIH Grants for Natural Product Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) & Coronavirus Disease 2019 (COVID-19)	NCCIH ORWH	Administrative supplement work that is proposed through PA-18-591 must be within the general scope of the research or training that is already supported. Applications that involve a change in scope (e.g., the addition of human subjects to a grant that has not been previously so coded and approved, the addition of vertebrate animals to a grant that has not been previously so coded and approved) must apply through PA-18-935. Due Date: applications will be accepted on a rolling basis through August 17, 2020.
NOT-OD-20-107	Notice of Special Interest (NOSI): Administrative Supplements to Existing NIH ECHO Cooperative Agreements (Admin Supp - Clinical Trial Not Allowed) for Coronavirus Disease 2019 (COVID-19) – related Research	OD	Administrative supplement work that is proposed through PA-18-591 must be within the general scope of the research or training that is already supported. Due Date: June 30, 2020 (extended from June 23, 2020: NOT-OD-20-117).
NOT-DC-20-008	Notice of Special Interest (NOSI): NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders	NIDCD	Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice. PA-18-334 - NIDCD Clinical Trials in Communication Disorders (R01 Clinical Trial Required) PA-20-185- NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) PA-20-184 – NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required) PA-20-196 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required) PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) PA-20-194 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) Due Date: This notice applies to due dates on or after October 5, 2020 and subsequent receipt dates through September 8, 2022
NOT-MH-20-053	Notice of Special Interest (NOSI): Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19	NIMH NEI NHLBI NIA NIAAA NICHD NIDCD NIDCR NIDDK NIDA NINR NIMHD NCCIH NCATS The following NIH Offices may co-fund applications assigned to those I/Cs: SGMRO ODP OBSSR ORWH	Administrative supplement work that is proposed through PA-18-591 must be within the general scope of the research or training that is already supported. Applications that involve a change in scope (e.g., the addition of human subjects to a grant that has not been previously so coded and approved, the addition of vertebrate animals to a grant that has not been previously so coded and approved) must apply through PA-18-935. Due Date: applications will be accepted on a rolling basis from June 10, 2020 through December 15, 2020, by 5:00 PM local time of applicant organization; applications submitted before July 15, 2020 will be considered for funding in in Fiscal Year 2020; and applications received after July 16, 2020 may be held for consideration in Fiscal Year 2021 and not be eligible for funding until October 2020.
NOT-MD-20-022	Notice of Special Interest (NOSI): Competitive and Administrative Supplements for Community Interventions to Reduce the Impact of COVID-19 on Health Disparity and Other Vulnerable Populations	NEI NHLBI NIA NIAAA NICHD NIDCD NIDCR NIDDK NIDA NIEHS NIMH NCCIH NCATS The following NIH Offices may co-fund applications assigned to those I/Cs: SGMRO ODP OBSSR ORWH	Administrative supplement work that is proposed through PA-18-591 must be within the general scope of the research or training that is already supported. Applications that involve a change in scope (e.g., the addition of human subjects to a grant that has not been previously so coded and approved, the addition of vertebrate animals to a grant that has not been previously so coded and approved) must apply through PA-18-935. Due Date: applications will be accepted on a rolling basis from June 10, 2020 through December 15, 2020 by 5:00 PM local time of the applicant organization. This NOSI expires on December 30, 2020; applications submitted before July 15, 2020 will be considered for funding in in Fiscal Year 2020; and applications received after July 16, 2020 may be held for consideration in Fiscal Year 2021 and not be eligible for funding until October 2020.
NOT-OD-20-119	Notice of Special Interest (NOSI): Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications (SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations	OD NIMHD NIA NEI NHLBI NHGRI NIAAA NIAID NIAMS NIBIB NICHD NIDCD NIDCR NIDDK NIDA NIEHS NIGMS NIMH NINDS NINR NLM FIC NCCIH NCATS NCI The following NIH Offices may co-fund applications assigned to those I/Cs: SGMRO THRO OD ODP OBSSR ORWH	Applications in response to this NOSI must be submitted using the Emergency Competitive Revision to Existing NIH Awards: PA-20-135 (or its subsequent reissued equivalents). Due Date: August 7, 2020 or September 8, 2020. NOT-OD-20-138: Notice of Correction to NOT-OD-20-119, NOT-OD-20-120, NOT-OD-20-121 Eligibility Section NOT-OD-20-157: Notice of Correction to NOT-OD-20-119, NOT-OD-20-120 Eligibility Section
NOT-OD-20-120	Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations	OD NIMHD NIA NEI NHLBI NHGRI NIAAA NIAID NIAMS NIBIB NICHD NIDCD NIDCR NIDDK NIDA NIEHS NIGMS NIMH NINDS NINR NLM FIC NCCIH NCATS NCI The following NIH Offices may co-fund applications assigned to those I/Cs: SGMRO THRO OD ODP OBSSR ORWH	Applications in response to this NOSI must be submitted using the Emergency Competitive Revision to Existing NIH Awards: PA-20-135 (or its subsequent reissued equivalents). Due Date: August 7, 2020 or September 8, 2020. NOT-OD-20-138: Notice of Correction to NOT-OD-20-119, NOT-OD-20-120, NOT-OD-20-121 Eligibility Section
NOT-OD-20-121	Notice of Special Interest (NOSI): Limited Competition for Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations	OD NIMHD NIA NEI NHLBI NHGRI NIAAA NIAID NIAMS NIBIB NICHD NIDCD NIDCR NIDDK NIDA NIEHS NIGMS NIMH NINDS NINR NLM FIC NCCIH NCATS NCI The following NIH Offices may co-fund applications assigned to those I/Cs: SGMRO THRO OD ODP OBSSR ORWH	Applications in response to this NOSI must be submitted using the Emergency Competitive Revision to Existing NIH Awards: PA-20-135 (or its subsequent reissued equivalents). Due Date: August 7, 2020. NOT-OD-20-138: Notice of Correction to NOT-OD-20-119, NOT-OD-20-120, NOT-OD-20-121 Eligibility Section
NOT-TR-20-029	Notice of Special Interest (NOSI): New Administrative Supplement Applications to UL1 and U24 CTSA Awards to Address COVID-19 Public Heath Need	NCATS	CTSA (CTRI) award specific. Administrative supplement work that is proposed through PA-18-591 must be within the general scope of the research or training that is already supported. Due Date: applications will be accepted immediately and on a rolling basis through November 10, 2020
NOT-OD-20-129	Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) in Individuals with Down Syndrome for the INCLUDE Project	OD NHLBI NHGRI NIA NIAID NIAMS NICHD NIDCD NIDCR NIDDK NIEHS NINDS NIMHD NCCIH NCATS ORIP NCI	Administrative supplement work that is proposed through PA-18-591 must be within the general scope of the research or training that is already supported. Applications that involve a change in scope (e.g., the addition of human subjects to a grant that has not been previously so coded and approved, the addition of vertebrate animals to a grant that has not been previously so coded and approved) must apply through PA-18-935. Due Date: July 13, 2020, November 12, 2020, March 12, 2021, and July 12, 2021
NOT-CA-20-082	Notice of Special Interest (NOSI): National Cancer Institute (NCI) Emergency Administrative Supplements for Research and Training Continuity of Postdoctoral Fellows during Coronavirus Disease 2019 (COVID-19)	NCI	Administrative supplement work that is proposed through PA-18-591 must be within the general scope of the research or training that is already supported. Due Date: applications will be accepted on a rolling basis from July 6, 2020, through August 14, 2020.
NOT-AI-20-059	Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Select Research Activities related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)	NIAID	Applications in response to this NOSI must be submitted using the Emergency Competitive Revision to Existing NIH Awards: PA-20-135 (or its subsequent reissued equivalents). Due Date: applications will be accepted on a rolling basis 07/02/2020 to 07/02/2021. This replaced NOT-AI-20-034.
NOT-OD-20-159	Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Wastewater Surveillance Research for Public Health Response to Coronavirus Disease 2019 (COVID-19)	OD NLM	Applications in response to this NOSI must be submitted using the Emergency Competitive Revision to Existing NIH Awards: PA-20-135 (or its subsequent reissued equivalents). Due Date: 08/21/2020.
NOT-OD-20-152	Availability of Emergency Competitive Revisions for Chemosensory Testing as a COVID-19 Screening Tool	OD NIA NICHD NIDCD NIDCR NINDS NINR	Applications in response to this NOSI must be submitted using the Emergency Competitive Revision to Existing NIH Awards: PA-20-135 (or its subsequent reissued equivalents). Due Date: 09/15/2020
NOT-AI-20-065	Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2	NIAID	Applications in response to this NOSI must be submitted using PAR-18-633 NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) (or its subsequent reissued equivalents). Due Date: September 14, 2020; October 14, 2020; November 14, 2020; December 14, 2020; January 14, 2021; February 14, 2021; March 14, 2021; April 14, 2021; May 14, 2021; June 14, 2021; July 14, 2021; ; August 14, 2021; and September 14, 2021.

Other Relevant Resources Related to COVID-19

Council on Governmental Relations (COGR):

CDC: Coronavirus (COVID-19)

Office of Management and Budget (OMB)

OMB M-20-26 Extension of Administrative Relief for Recipients and Applicants of Federal Financial Assistance (COVID-19)

This memorandum provides an extension of [M-20-11], Allowability of salaries and other project activities (item 6 in M-20-17) through September 30, 2020 and [M-20-17], Extension of Single Audit submission (item 13 in M-20-17) through December 31 , 2020 to allow a responsible transition to normal operations. In light of the limited funding resources provided for each Federal award to achieve its own public performance goals, OMB added restrictions to the flexibilities allowed in [M-20-11], Allowability of salaries and other project activities. All flexibilities provided in this memorandum are time limited and will expire on September 30, 2020. M-20-17
and M-20-20 are rescinded. M-20-11 expires on July 26, 2020.

OMB M-20-21 Implementation Guidance for Supplemental Funding Provided in Response to the Coronavirus Disease 2019 (COVID-19)

This memorandum directs agencies to leverage and continue to employ existing financial transparency and accountability mechanisms wherever possible. In balancing speed with transparency, agencies are to consider the three core principles below:

Mission achievement - Federal managers and recipients at all levels should use data and evidence to achieve program objectives;
Expediency - Agencies should rapidly issue awards and fund programs to meet crucial needs; and
Transparency and accountability - Agencies must report information on awards to provide the public with information in a clear, accurate, and timely manner

OMB M-20-20 Repurposing Existing Federal Financial Assistance Programs and Awards to Support the Emergency Response to the Novel Coronavirus (COVID-19)

OMB is issuing a class exception that allows Federal awarding agencies to repurpose their federal assistance awards (in whole or part) to support the COVID-19 response, as consistent with applicable laws.
Rescinded 6/18/2020.

OMB M-20-17 Administrative Relief for Recipients and Applicants of Federal Financial

“This memorandum provides similar administrative relief listed in M-20-11 to an expanded scope of recipients affected by the loss of operational capacity and increased costs due to the COVID-19 crisis. Many of the operational impacts and costs are unknowable at this point, as they will depend on the spread of the coronavirus and response dictated by public health needs. This memorandum provides short term relief for administrative, financial management, and audit requirements under 2 CFR Part 200, Uniform Administrative Requirements, Cost principles and Audit Requirements for Federal Awards, without compromising Federal financial assistance accountability requirements. As program managers are considering administrative relief, they should be prudent in their stewardship of Federal resources which includes giving consideration to potential offsets-e.g. reduction in training and travel. In addition, the flexibilities provided within this memorandum, agencies are reminded of their existing flexibility to issue exceptions on a case-by-case basis in accordance with 2 CFR § 200.102, Exceptions. M20-11 shall continue to apply, and Appendix A describes the exceptions granted under this memorandum to recipients affected by the loss of operational capacity. These exceptions are time limited and will be reassessed by OMB within 90 days of this Memo.”
Rescinded 6/18/2020.

OMB M-20-11 Administrative Relief for Recipients and Applicants of Federal Financial Assistance Directly Impacted by the Novel Coronavirus (COVID-19)

"The Office of Management and Budget (OMB) has identified the following agency actions to relieve short term administrative, financial management and audit requirements under 2 CFR 200, Uniform Administrative Requirements, Cost principles and Audit Requirements for Federal Awards, without compromising Federal financial assistance accountability requirements. In accordance with 2 CFR § 200.102, Exceptions, OMB is allowing Federal agencies to grant class exceptions in instances where the agency has determined that the purpose of the Federal awards is to support the continued research and services necessary to carry out the emergency response related to COVID-19. Further, agencies are reminded of their existing flexibility to issue exceptions on a case-by-case basis in accordance with 2 CFR § 200.102, Exceptions. The Administration will evaluate if these flexibilities should be extended to recipients whose operations have been adversely impacted in the emergency response related to COVID-19 at a later date."
M-20-11 expires on July 26, 2020.